Published in Expert Rev Anticancer Ther on December 01, 2012
The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer (2014) 0.98
Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS One (2015) 0.85
NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression. Purinergic Signal (2014) 0.77
Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: Analysis of 125 cases. Urol Ann (2015) 0.75
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. Urology (2010) 2.99
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J (2011) 2.50
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol (2010) 2.11
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int (2011) 1.85
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther (2009) 1.80
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol (2012) 1.65
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol (2008) 1.54
The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. J Endourol (2011) 1.53
Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int (2011) 1.50
Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol (2009) 1.49
Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol (2007) 1.49
Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int (2012) 1.46
An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec. Can Urol Assoc J (2008) 1.45
Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J (2008) 1.42
Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Urology (2010) 1.42
An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol (2009) 1.42
Are men on 5α-reductase inhibitors appropriately referred to urology? A survey of primary care physicians. BJU Int (2010) 1.41
Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol (2010) 1.40
Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer (2007) 1.39
Incorporation of the da Vinci Surgical Skills Simulator at urology Objective Structured Clinical Examinations (OSCEs): a pilot study. Can J Urol (2016) 1.39
Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int (2010) 1.31
Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations. Clin Nutr (2013) 1.26
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.21
Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol (2007) 1.21
Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer (2007) 1.20
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int (2010) 1.15
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res (2010) 1.15
Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther (2009) 1.15
Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system. Can Urol Assoc J (2011) 1.11
Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol (2010) 1.11
Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.10
Renal cell carcinoma with inferior vena caval extention: impact of tumour extent on surgical outcome. BJU Int (2009) 1.07
Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Can Urol Assoc J (2011) 1.07
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol (2010) 1.06
Dietary habits and prostate cancer detection: a case-control study. Can Urol Assoc J (2008) 1.06
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol (2010) 1.04
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J (2013) 1.04
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J (2013) 1.02
Accuracy of urine cytology and the significance of an atypical category. Am J Clin Pathol (2009) 1.02
Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer (2008) 1.01
Malignant mesothelioma of the tunica vaginalis. Urology (2005) 1.00
Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int (2010) 0.99
Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol (2010) 0.99
Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU Int (2012) 0.98
Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol (2012) 0.96
Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J (2010) 0.95
Management of urethral recurrence after orthotopic urinary diversion. BJU Int (2009) 0.94
External stoma and peristomal complications following radical cystectomy and ileal conduit diversion: a systematic review. Ostomy Wound Manage (2010) 0.94
Plasmacytoid urothelial carcinoma of the bladder: a case report. Cases J (2009) 0.93
Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol (2010) 0.90
Demographic analysis of randomized controlled trials in bladder cancer. BJU Int (2012) 0.89
Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology (2007) 0.88
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. Eur Urol (2012) 0.88
Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World J Urol (2012) 0.88
Contemporary management of muscle-invasive bladder cancer. Int J Clin Oncol (2008) 0.87
Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system. Can Urol Assoc J (2013) 0.87
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol (2007) 0.87
Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int (2011) 0.87
Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol (2012) 0.87
Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Hum Pathol (2013) 0.86
Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol (2011) 0.86
Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int (2011) 0.86
Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int (2011) 0.86
Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment. PLoS One (2013) 0.86
Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol (2010) 0.85
Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol (2010) 0.85
Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int (2009) 0.85
Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: a population-based study. BJU Int (2014) 0.85
Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol (2010) 0.84
Organ-sparing strategies in the management of invasive bladder cancer. Expert Rev Anticancer Ther (2009) 0.84
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int (2010) 0.84
Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. Can Urol Assoc J (2012) 0.84
Extensive renal infarction following percutaneous biopsy of a small renal mass: A case report. Can Urol Assoc J (2013) 0.83
Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol (2012) 0.82
Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int (2011) 0.82
Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU Int (2012) 0.82
Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. Can Urol Assoc J (2012) 0.82
Impact of treatment delay in patients with bladder cancer managed with partial cystectomy in Quebec: a population-based study. Can Urol Assoc J (2009) 0.82
A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol (2010) 0.81
Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU Int (2012) 0.81
pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol (2010) 0.81
Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World J Urol (2011) 0.81